BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, Takii Y, Koyabu M, Yokoyama T, Migita K, Daikoku M, Abiru S, Yatsuhashi H, Takezaki E, Masaki N, Sugi K, Honda K, Adachi H, Nishi H, Watanabe Y, Nakamura Y, Shimada M, Komatsu T, Saito A, Saoshiro T, Harada H, Sodeyama T, Hayashi S, Masumoto A, Sando T, Yamamoto T, Sakai H, Kobayashi M, Muro T, Koga M, Shums Z, Norman GL, Ishibashi H. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007;45:118-27. [PMID: 17187436 DOI: 10.1002/hep.21472] [Cited by in Crossref: 251] [Cited by in F6Publishing: 208] [Article Influence: 16.7] [Reference Citation Analysis]
Number Citing Articles
1 Lenti MV, Rossi CM, Melazzini F, Gastaldi M, Bugatti S, Rotondi M, Bianchi PI, Gentile A, Chiovato L, Montecucco C, Corazza GR, Di Sabatino A. Seronegative autoimmune diseases: A challenging diagnosis. Autoimmun Rev 2022;21:103143. [PMID: 35840037 DOI: 10.1016/j.autrev.2022.103143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chen S, Li MQ, Duan WJ, Li BE, Li SX, Lv TT, Ma L, Jia JD. Concomitant extrahepatic autoimmune diseases do not compromise the long-term outcomes of primary biliary cholangitis. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00127-8. [PMID: 35668014 DOI: 10.1016/j.hbpd.2022.05.009] [Reference Citation Analysis]
3 Kayser C, Dutra LA, Dos Reis-Neto ET, Castro CHM, Fritzler MJ, Andrade LEC. The Role of Autoantibody Testing in Modern Personalized Medicine. Clin Rev Allergy Immunol 2022. [PMID: 35244870 DOI: 10.1007/s12016-021-08918-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 You H, Ma X, Efe C, Wang G, Jeong SH, Abe K, Duan W, Chen S, Kong Y, Zhang D, Wei L, Wang FS, Lin HC, Yang JM, Tanwandee T, Gani RA, Payawal DA, Sharma BC, Hou J, Yokosuka O, Dokmeci AK, Crawford D, Kao JH, Piratvisuth T, Suh DJ, Lesmana LA, Sollano J, Lau G, Sarin SK, Omata M, Tanaka A, Jia J. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatol Int 2022. [PMID: 35119627 DOI: 10.1007/s12072-021-10276-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Andrade LEC, Damoiseaux J, Vergani D, Fritzler MJ. Antinuclear antibodies (ANA) as a criterion for classification and diagnosis of systemic autoimmune diseases. Journal of Translational Autoimmunity 2022. [DOI: 10.1016/j.jtauto.2022.100145] [Reference Citation Analysis]
6 Chen Q, Zhong R, Dong K, Wang Y, Kui Y, Ma B, Wen X, Jin Q. The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China. Dig Liver Dis 2021:S1590-8658(21)00816-1. [PMID: 34789400 DOI: 10.1016/j.dld.2021.10.011] [Reference Citation Analysis]
7 Himoto T, Yamamoto S, Morimoto K, Tada S, Mimura S, Fujita K, Tani J, Morishita A, Masaki T. Clinical impact of antibodies to Sp100 on a bacterial infection in patients with primary biliary cholangitis. J Clin Lab Anal 2021;35:e24040. [PMID: 34623692 DOI: 10.1002/jcla.24040] [Reference Citation Analysis]
8 Trivedi PJ, Hirschfield GM. Recent advances in clinical practice: epidemiology of autoimmune liver diseases. Gut 2021;70:1989-2003. [PMID: 34266966 DOI: 10.1136/gutjnl-2020-322362] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
9 Cristoferi L, Gerussi A, Invernizzi P. Anti-gp210 and other anti-nuclear pore complex autoantibodies in primary biliary cholangitis: What we know and what we should know. Liver Int 2021;41:432-5. [PMID: 34542229 DOI: 10.1111/liv.14791] [Reference Citation Analysis]
10 Zeng X, Li S, Tang S, Li X, Zhang G, Li M, Zeng X, Hu C. Changes of Serum IgG Glycosylation Patterns in Primary Biliary Cholangitis Patients. Front Immunol 2021;12:669137. [PMID: 34248947 DOI: 10.3389/fimmu.2021.669137] [Reference Citation Analysis]
11 Ben Lamine Z, Ben Jazia I, Ben Ahmed M, Ben Slama A, Baccouche A, Slama F, Jemaa A, Ghedira I, Mankaï A. Anti-gp210 and anti-Sp100 antibodies in primary biliary cholangitis. Arab J Gastroenterol 2021:S1687-1979(21)00028-9. [PMID: 34090832 DOI: 10.1016/j.ajg.2021.05.006] [Reference Citation Analysis]
12 Li H, Guan Y, Han C, Zhang Y, Liu Q, Wei W, Ma Y. The pathogenesis, models and therapeutic advances of primary biliary cholangitis. Biomed Pharmacother 2021;140:111754. [PMID: 34044277 DOI: 10.1016/j.biopha.2021.111754] [Reference Citation Analysis]
13 Cargill T, Culver EL. The Role of B Cells and B Cell Therapies in Immune-Mediated Liver Diseases. Front Immunol 2021;12:661196. [PMID: 33936097 DOI: 10.3389/fimmu.2021.661196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Papamichalis PA, Zachou K, Papamichali RA, Ioannou M, Gatselis NK, Dalekos GN, Koukoulis GK. Promyelocytic Leukemia Antigen Expression: a Histological Marker for Primary Biliary Cholangitis Diagnosis? J Transl Int Med 2021;9:43-51. [PMID: 33850801 DOI: 10.2478/jtim-2021-0008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Lleo A, Wang GQ, Gershwin ME, Hirschfield GM. Primary biliary cholangitis. Lancet 2020;396:1915-26. [PMID: 33308474 DOI: 10.1016/S0140-6736(20)31607-X] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
16 Fujita K, Yamasaki K, Morishita A, Shi T, Tani J, Nishiyama N, Kobara H, Himoto T, Yatsuhashi H, Masaki T. Albumin platelet product as a novel score for liver fibrosis stage and prognosis. Sci Rep 2021;11:5345. [PMID: 33674669 DOI: 10.1038/s41598-021-84719-3] [Reference Citation Analysis]
17 Maltez N, Choi MY, Troyanov Y, Wang M, Jantz M, Fritzler MJ, Baron M, Hudson M; Canadian Scleroderma Research Group. Trigeminal neuralgia in systemic sclerosis. Semin Arthritis Rheum 2021;51:318-23. [PMID: 33461050 DOI: 10.1016/j.semarthrit.2021.01.001] [Reference Citation Analysis]
18 Reig A, Norman GL, Parés A. Response to Granito et al. Am J Gastroenterol 2021;116:217. [PMID: 33065591 DOI: 10.14309/ajg.0000000000000980] [Reference Citation Analysis]
19 Tanaka A. Current understanding of primary biliary cholangitis. Clin Mol Hepatol 2021;27:1-21. [PMID: 33264835 DOI: 10.3350/cmh.2020.0028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Reig A, Norman GL, Garcia M, Shums Z, Ruiz-Gaspà S, Bentow C, Mahler M, Romera MA, Vinas O, Pares A. Novel Anti-Hexokinase 1 Antibodies Are Associated With Poor Prognosis in Patients With Primary Biliary Cholangitis. Am J Gastroenterol 2020;115:1634-41. [PMID: 32467507 DOI: 10.14309/ajg.0000000000000690] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
21 Haldar D, Janmohamed A, Plant T, Davidson M, Norman H, Russell E, Serevina O, Chung K, Qamar K, Gunson B, Hansen B, Richter A, Trivedi PJ, Hirschfield GM. Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis. Liver Int 2021;41:535-44. [PMID: 33022821 DOI: 10.1111/liv.14688] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Leung KK, Deeb M, Hirschfield GM. Review article: pathophysiology and management of primary biliary cholangitis. Aliment Pharmacol Ther. [DOI: 10.1111/apt.16023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
23 Fischer HP, Goltz D. [Autoimmune liver diseases]. Pathologe 2020;41:444-56. [PMID: 32749523 DOI: 10.1007/s00292-020-00807-7] [Reference Citation Analysis]
24 Natarajan Y, Tansel A, Patel P, Emologu K, Shukla R, Qureshi Z, El-Serag HB, Thrift AP, Kanwal F. Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Dig Dis Sci 2021;66:2439-51. [PMID: 32743773 DOI: 10.1007/s10620-020-06498-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
25 Levy C, Bowlus CL. Role of Antinuclear Antibodies in Primary Biliary Cholangitis. Am J Gastroenterol 2020;115:1604-6. [DOI: 10.14309/ajg.0000000000000765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Fukushima M, Miyaaki H, Sasaki R, Haraguchi M, Miuma S, Ishimaru H, Hidaka M, Okudaira S, Eguchi S, Futakuchi M, Kusano H, Kage M, Nakao K. Inferior Vena Cava Anomalies with Portal Vein System Continuation Presenting as Portal Hypertension with a Long-term Follow-up. Intern Med 2020;59:2897-901. [PMID: 32713916 DOI: 10.2169/internalmedicine.4956-20] [Reference Citation Analysis]
27 Zhao DT, Liu YM, Han Y, Zhang HP, Zhao Y, Yan HP. Fluctuations of antimitochondrial antibodies and anti-gp210 antibody in a patient with primary biliary cholangitis and Sjögren syndrome with subsequent autoimmune hemolytic anemia: A case report. Medicine (Baltimore) 2020;99:e18856. [PMID: 32011506 DOI: 10.1097/MD.0000000000018856] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Takano K, Saeki C, Oikawa T, Hidaka A, Mizuno Y, Ishida J, Takakura K, Nakano M, Torisu Y, Amano K, Ishikawa T, Zeniya M, Tsubota A, Saruta M. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate. Journal of Gastroenterology and Hepatology 2020;35:663-72. [DOI: 10.1111/jgh.14900] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
29 Cristoferi L, Nardi A, Invernizzi P, Mells G, Carbone M. Individualizing Care: Management Beyond Medical Therapy. Surg Oncol Clin N Am 2020;29:87-103. [PMID: 31757316 DOI: 10.1016/j.soc.2019.08.007] [Reference Citation Analysis]
30 Abdulkarim M, Zenouzi R, Sebode M, Schulz L, Quaas A, Lohse AW, Schramm C, Weiler-Normann C. Sex differences in clinical presentation and prognosis in patients with primary biliary cholangitis. Scand J Gastroenterol 2019;54:1391-6. [PMID: 31692389 DOI: 10.1080/00365521.2019.1683226] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
31 Huang C, Han W, Wang C, Liu Y, Chen Y, Duan Z. Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis. Dis Markers 2019;2019:9121207. [PMID: 31737133 DOI: 10.1155/2019/9121207] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
32 Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D, Vierling JM, Adams D, Alpini G, Banales JM, Beuers U, Björnsson E, Bowlus C, Carbone M, Chazouillères O, Dalekos G, De Gottardi A, Harada K, Hirschfield G, Invernizzi P, Jones D, Krawitt E, Lanzavecchia A, Lian ZX, Ma X, Manns M, Mavilio D, Quigley EM, Sallusto F, Shimoda S, Strazzabosco M, Swain M, Tanaka A, Trauner M, Tsuneyama K, Zigmond E, Gershwin ME. The challenges of primary biliary cholangitis: What is new and what needs to be done. J Autoimmun 2019;105:102328. [PMID: 31548157 DOI: 10.1016/j.jaut.2019.102328] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
33 Vetter M, Kremer AE. [Primary biliary cholangitis-established and novel therapies]. Internist (Berl) 2018;59:544-50. [PMID: 29691599 DOI: 10.1007/s00108-018-0427-0] [Reference Citation Analysis]
34 Fujita K, Nomura T, Morishita A, Shi T, Oura K, Tani J, Kobara H, Tsutsui K, Himoto T, Masaki T. Prediction of Transplant-Free Survival through Albumin-Bilirubin Score in Primary Biliary Cholangitis. J Clin Med 2019;8:E1258. [PMID: 31430975 DOI: 10.3390/jcm8081258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
35 Arvaniti P, Zachou K, Lyberopoulou A, Gatselis NK, Brooks WH, Dalekos GN, Renaudineau Y. Epigenetic Modifications in Generalized Autoimmune Epithelitis: Sjögren's Syndrome and Primary Biliary Cholangitis. Epigenomes 2019;3:15. [PMID: 34968227 DOI: 10.3390/epigenomes3030015] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
36 Wang C, Zheng X, Jiang P, Tang R, Gong Y, Dai Y, Wang L, Xu P, Sun W, Wang L, Han C, Jiang Y, Wei Y, Zhang K, Wu J, Shao Y, Gao Y, Yu J, Hu Z, Zang Z, Zhao Y, Wu X, Dai N, Liu L, Nie J, Jiang B, Lin M, Li L, Li Y, Chen S, Shu L, Qiu F, Wu Q, Zhang M, Chen R, Jawed R, Zhang Y, Shi X, Zhu Z, Pei H, Huang L, Zhao W, Tian Y, Zhu X, Qiu H, Gershwin ME, Chen W, Seldin MF, Liu X, Sun L, Ma X. Genome-wide Association Studies of Specific Antinuclear Autoantibody Subphenotypes in Primary Biliary Cholangitis. Hepatology 2019;70:294-307. [PMID: 30854688 DOI: 10.1002/hep.30604] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
37 Taylor SA, Assis DN, Mack CL. The Contribution of B Cells in Autoimmune Liver Diseases. Semin Liver Dis 2019;39:422-31. [PMID: 31226726 DOI: 10.1055/s-0039-1688751] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
38 Dalekos GN, Gatselis NK. Variant and Specific Forms of Autoimmune Cholestatic Liver Diseases. Arch Immunol Ther Exp (Warsz) 2019;67:197-211. [PMID: 31165900 DOI: 10.1007/s00005-019-00550-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
39 Ronca V, Gerussi A, Cristoferi L, Carbone M, Invernizzi P. Precision medicine in primary biliary cholangitis. J Dig Dis 2019;20:338-45. [PMID: 31099953 DOI: 10.1111/1751-2980.12787] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
40 Ben-moshe S, Itzkovitz S. Spatial heterogeneity in the mammalian liver. Nat Rev Gastroenterol Hepatol 2019;16:395-410. [DOI: 10.1038/s41575-019-0134-x] [Cited by in Crossref: 125] [Cited by in F6Publishing: 86] [Article Influence: 41.7] [Reference Citation Analysis]
41 Ma W, Chen D. Immunological abnormalities in patients with primary biliary cholangitis. Clinical Science 2019;133:741-60. [DOI: 10.1042/cs20181123] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
42 Liu HM, Zhang HW, Lin R, Song Y, Zhou L, Wang BM, Liu WT. Clinical features of patients with refractory primary biliary cholangitis. Shijie Huaren Xiaohua Zazhi 2019; 27(4): 238-244 [DOI: 10.11569/wcjd.v27.i4.238] [Reference Citation Analysis]
43 Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology 2019;69:394-419. [PMID: 30070375 DOI: 10.1002/hep.30145] [Cited by in Crossref: 125] [Cited by in F6Publishing: 133] [Article Influence: 41.7] [Reference Citation Analysis]
44 Terziroli Beretta-piccoli B, Mieli-vergani G, Vergani D. The clinical usage and definition of autoantibodies in immune-mediated liver disease: A comprehensive overview. Journal of Autoimmunity 2018;95:144-58. [DOI: 10.1016/j.jaut.2018.10.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
45 Janmohamed A, Trivedi PJ. Patterns of disease progression and incidence of complications in primary biliary cholangitis (PBC). Best Pract Res Clin Gastroenterol 2018;34-35:71-83. [PMID: 30343713 DOI: 10.1016/j.bpg.2018.06.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Cristoferi L, Nardi A, Invernizzi P, Mells G, Carbone M. Individualizing Care: Management Beyond Medical Therapy. Clin Liver Dis 2018;22:545-61. [PMID: 30259852 DOI: 10.1016/j.cld.2018.03.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
47 Bossen L, Gerussi A, Lygoura V, Mells GF, Carbone M, Invernizzi P. Support of precision medicine through risk-stratification in autoimmune liver diseases – histology, scoring systems, and non-invasive markers. Autoimmunity Reviews 2018;17:854-65. [DOI: 10.1016/j.autrev.2018.02.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
48 Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hübscher S, Patanwala I, Pereira SP, Thain C, Thorburn D, Tiniakos D, Walmsley M, Webster G, Jones DEJ. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 2018;67:1568-94. [PMID: 29593060 DOI: 10.1136/gutjnl-2017-315259] [Cited by in Crossref: 124] [Cited by in F6Publishing: 101] [Article Influence: 31.0] [Reference Citation Analysis]
49 Sowa M, Kolenda R, Baumgart DC, Pratschke J, Papp M, Tornai T, Suchanski J, Bogdanos DP, Mytilinaiou MG, Hammermann J, Laass MW, Conrad K, Schramm C, Franke A, Roggenbuck D, Schierack P. Mucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype. Front Immunol 2018;9:1959. [PMID: 30233574 DOI: 10.3389/fimmu.2018.01959] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
50 Terziroli Beretta-Piccoli B, Stirnimann G, Cerny A, Semela D, Hessler R, Helbling B, Stickel F, Kalid-de Bakker C, Bihl F, Giostra E, Filipowicz Sinnreich M, Oneta C, Baserga A, Invernizzi P, Carbone M, Mertens J. Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland. Clin Rev Allergy Immunol 2018;54:295-306. [PMID: 29181702 DOI: 10.1007/s12016-017-8656-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
51 Aiba Y, Harada K, Ito M, Suematsu T, Aishima S, Hitomi Y, Nishida N, Kawashima M, Takatsuki M, Eguchi S, Shimoda S, Nakamura H, Komori A, Abiru S, Nagaoka S, Migita K, Yatsuhashi H, Tokunaga K, Nakamura M. Increased expression and altered localization of cathepsin Z are associated with progression to jaundice stage in primary biliary cholangitis. Sci Rep 2018;8:11808. [PMID: 30087368 DOI: 10.1038/s41598-018-30146-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
52 Kouroumalis E, Samonakis D, Voumvouraki A. Biomarkers for primary biliary cholangitis: current perspectives. Hepat Med 2018;10:43-53. [PMID: 29950909 DOI: 10.2147/HMER.S135337] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
53 Gulamhusein AF, Hirschfield GM. Pathophysiology of primary biliary cholangitis. Best Practice & Research Clinical Gastroenterology 2018;34-35:17-25. [DOI: 10.1016/j.bpg.2018.05.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
54 Goet JC, Harms MH, Carbone M, Hansen BE. Risk stratification and prognostic modelling in primary biliary cholangitis. Best Practice & Research Clinical Gastroenterology 2018;34-35:95-106. [DOI: 10.1016/j.bpg.2018.06.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
55 Joshita S, Umemura T, Usami Y, Yamashita Y, Norman GL, Sugiura A, Yamazaki T, Fujimori N, Kimura T, Matsumoto A, Igarashi K, Yoshizawa K, Ota M, Tanaka E. Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis. Sci Rep 2018;8:8159. [PMID: 29802350 DOI: 10.1038/s41598-018-26531-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
56 Nishida N, Aiba Y, Hitomi Y, Kawashima M, Kojima K, Kawai Y, Ueno K, Nakamura H, Yamashiki N, Tanaka T, Tamura S, Mori A, Yagi S, Soejima Y, Yoshizumi T, Takatsuki M, Tanaka A, Harada K, Shimoda S, Komori A, Eguchi S, Maehara Y, Uemoto S, Kokudo N, Nagasaki M, Tokunaga K, Nakamura M. NELFCD and CTSZ loci are associated with jaundice-stage progression in primary biliary cholangitis in the Japanese population. Sci Rep 2018;8:8071. [PMID: 29795304 DOI: 10.1038/s41598-018-26369-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
57 Sebode M, Weiler-Normann C, Liwinski T, Schramm C. Autoantibodies in Autoimmune Liver Disease-Clinical and Diagnostic Relevance. Front Immunol. 2018;9:609. [PMID: 29636752 DOI: 10.3389/fimmu.2018.00609] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
58 Nguyen HH, Shaheen AA, Baeza N, Lytvyak E, Urbanski SJ, Mason AL, Norman GL, Fritzler MJ, Swain MG. Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS). PLoS One 2018;13:e0193960. [PMID: 29554146 DOI: 10.1371/journal.pone.0193960] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
59 Tang R, Wei Y, Li Y, Chen W, Chen H, Wang Q, Yang F, Miao Q, Xiao X, Zhang H, Lian M, Jiang X, Zhang J, Cao Q, Fan Z, Wu M, Qiu D, Fang JY, Ansari A, Gershwin ME, Ma X. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut 2018;67:534-41. [PMID: 28213609 DOI: 10.1136/gutjnl-2016-313332] [Cited by in Crossref: 190] [Cited by in F6Publishing: 182] [Article Influence: 47.5] [Reference Citation Analysis]
60 Alfano AM, Romito A, Marchese C, Battistini M, Crotti G, Ferrini A, Mancinetti C, Manetta T, Mengozzi G, Merlach P, Migliardi M, Tambuzzo MT. Diagnostic accuracy of two tests for determination of anti-m2 in the diagnosis of primary biliary cirrhosis: Is it possible to predict the course of the disease? Immunol Res 2017;65:299-306. [PMID: 27475095 DOI: 10.1007/s12026-016-8838-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
61 Ide R, Oshita A, Nishisaka T, Nakahara H, Aimitsu S, Itamoto T. Primary biliary cholangitis metachronously complicated with combined hepatocellular carcinoma-cholangiocellular carcinoma and hepatocellular carcinoma. World J Hepatol 2017; 9(36): 1378-1384 [PMID: 29359023 DOI: 10.4254/wjh.v9.i36.1378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
62 Burman BE, Jhaveri MA, Kowdley KV. An Update on the Treatment and Follow-up of Patients with Primary Biliary Cholangitis. Clinics in Liver Disease 2017;21:709-23. [DOI: 10.1016/j.cld.2017.06.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
63 Terziroli Beretta-piccoli B, Invernizzi P, Gershwin ME, Mainetti C. Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review. Clinic Rev Allerg Immunol 2017;53:394-412. [DOI: 10.1007/s12016-017-8649-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
64 Brahim I, Brahim I, Hazime R, Admou B. [Autoimmune hepatitis: Immunological diagnosis]. Presse Med 2017;46:1008-19. [PMID: 28919271 DOI: 10.1016/j.lpm.2017.08.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
65 Corrigan M, Hirschfield GM. Autoimmune liver disease: evaluating overlapping and cross-over presentations-a case-based discussion. Frontline Gastroenterol 2016;7:240-5. [PMID: 28839864 DOI: 10.1136/flgastro-2016-100698] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
66 Honda S, Sawada K, Hasebe T, Nakajima S, Fujiya M, Okumura T. Tegafur-uracil-induced rapid development of advanced hepatic fibrosis. World J Gastroenterol 2017; 23(31): 5823-5828 [PMID: 28883709 DOI: 10.3748/wjg.v23.i31.5823] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
67 Invernizzi P, Floreani A, Carbone M, Marzioni M, Craxi A, Muratori L, Vespasiani Gentilucci U, Gardini I, Gasbarrini A, Kruger P, Mennini FS, Ronco V, Lanati E, Canonico PL, Alvaro D. Primary Biliary Cholangitis: advances in management and treatment of the disease. Digestive and Liver Disease 2017;49:841-6. [DOI: 10.1016/j.dld.2017.05.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
68 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67:145-172. [PMID: 28427765 DOI: 10.1016/j.jhep.2017.03.022] [Cited by in Crossref: 409] [Cited by in F6Publishing: 326] [Article Influence: 81.8] [Reference Citation Analysis]
69 Floreani A, Tanaka A, Bowlus C, Gershwin ME. Geoepidemiology and changing mortality in primary biliary cholangitis. J Gastroenterol 2017;52:655-62. [DOI: 10.1007/s00535-017-1333-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
70 Yang F, Yang Y, Wang Q, Wang Z, Miao Q, Xiao X, Wei Y, Bian Z, Sheng L, Chen X, Qiu D, Fang J, Tang R, Gershwin ME, Ma X. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210. Aliment Pharmacol Ther 2017;45:733-43. [PMID: 28083929 DOI: 10.1111/apt.13927] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 8.6] [Reference Citation Analysis]
71 Umemura T, Sekiguchi T, Joshita S, Yamazaki T, Fujimori N, Shibata S, Ichikawa Y, Komatsu M, Matsumoto A, Shums Z, Norman GL, Tanaka E, Ota M. Association between serum soluble CD14 and IL-8 levels and clinical outcome in primary biliary cholangitis. Liver Int 2017;37:897-905. [DOI: 10.1111/liv.13316] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
72 Yang F, Wang Q, Wang Z, Miao Q, Xiao X, Tang R, Chen X, Bian Z, Zhang H, Yang Y. The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis. Clin Rev Allergy Immunol. 2016;50:114-123. [PMID: 26411425 DOI: 10.1007/s12016-015-8516-5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
73 Ali AH, Tabibian JH, Carey EJ, Lindor KD. Emerging drugs for the treatment of Primary Biliary Cholangitis. Expert Opin Emerg Drugs 2016;21:39-56. [PMID: 26901615 DOI: 10.1517/14728214.2016.1150999] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
74 Gatselis NK, Dalekos GN. Molecular diagnostic testing for primary biliary cholangitis. Expert Review of Molecular Diagnostics 2016;16:1001-10. [DOI: 10.1080/14737159.2016.1217159] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
75 Carbone M, Ronca V, Bruno S, Invernizzi P, Mells GF. Toward precision medicine in primary biliary cholangitis. Digestive and Liver Disease 2016;48:843-50. [DOI: 10.1016/j.dld.2016.05.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
76 Leung PS, Choi J, Yang G, Woo E, Kenny TP, Gershwin ME. A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis. Expert Rev Mol Diagn 2016;16:697-705. [PMID: 26953925 DOI: 10.1586/14737159.2016.1164038] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
77 Trivedi PJ, Corpechot C, Pares A, Hirschfield GM. Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists. Hepatology 2016;63:644-59. [PMID: 26290473 DOI: 10.1002/hep.28128] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
78 Shimoda S, Tanaka A. It is time to change primary biliary cirrhosis (PBC): New nomenclature from "cirrhosis" to "cholangitis", and upcoming treatment based on unveiling pathology. Hepatol Res 2016;46:407-15. [PMID: 26518139 DOI: 10.1111/hepr.12615] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
79 Juliusson G, Imam M, Björnsson ES, Talwalkar JA, Lindor KD. Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. Scand J Gastroenterol. 2016;51:745-752. [PMID: 26776319 DOI: 10.3109/00365521.2015.1132337] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
80 Bittencourt PL, Cançado ELR, Couto CA, Levy C, Porta G, Silva AEB, Terrabuio DRB, Carvalho Filho RJD, Chaves DM, Miura IK, Codes L, Faria LC, Evangelista AS, Farias AQ, Gonçalves LL, Harriz M, Lopes Neto EPA, Luz GO, Oliveira P, Oliveira EMGD, Schiavon JLN, Seva-pereira T, Parise ER. Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver. Arq Gastroenterol 2015;52:15-46. [DOI: 10.1590/s0004-28032015000500002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
81 Raszeja-Wyszomirska J, Wunsch E, Krawczyk M, Rigopoulou EI, Kostrzewa K, Norman GL, Bogdanos DP, Milkiewicz P. Assessment of health related quality of life in polish patients with primary biliary cirrhosis. Clin Res Hepatol Gastroenterol. 2016;40:471-479. [PMID: 26621536 DOI: 10.1016/j.clinre.2015.10.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
82 Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet. 2015;386:1565-1575. [PMID: 26364546 DOI: 10.1016/s0140-6736(15)00154-3] [Cited by in Crossref: 277] [Cited by in F6Publishing: 121] [Article Influence: 39.6] [Reference Citation Analysis]
83 Sclair SN, Little E, Levy C. Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clin Transl Gastroenterol 2015;6:e109. [PMID: 26312413 DOI: 10.1038/ctg.2015.33] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
84 Honda A, Ikegami T, Matsuzaki Y. Anti-gp210 and anti-centromere antibodies for the prediction of PBC patients with an incomplete biochemical response to UDCA and bezafibrate. Hepatol Res 2015;45:827-8. [PMID: 26205698 DOI: 10.1111/hepr.12461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Reshetnyak VI. Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis. World J Gastroenterol 2015; 21(25): 7683-7708 [PMID: 26167070 DOI: 10.3748/wjg.v21.i25.7683] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
86 Zhang H, Bernuzzi F, Lleo A, Ma X, Invernizzi P. Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases. Mediators Inflamm 2015;2015:436450. [PMID: 26146463 DOI: 10.1155/2015/436450] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
87 Umemura T, Joshita S, Sekiguchi T, Usami Y, Shibata S, Kimura T, Komatsu M, Matsumoto A, Ota M, Tanaka E. Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis. Am J Gastroenterol. 2015;110:857-864. [PMID: 25916223 DOI: 10.1038/ajg.2015.118] [Cited by in Crossref: 95] [Cited by in F6Publishing: 86] [Article Influence: 13.6] [Reference Citation Analysis]
88 Takeyama Y, Tsuchiya N, Kunimoto H, Fukunaga A, Sakurai K, Hirano G, Yokoyama K, Morihara D, Anan A, Irie M. Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging as a useful detection method for advanced primary biliary cirrhosis. Hepatol Res. 2015;45:E108-E114. [PMID: 25560223 DOI: 10.1111/hepr.12470] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
89 Bunchorntavakul C, Reddy KR. Diagnosis and Management of Overlap Syndromes. Clinics in Liver Disease 2015;19:81-97. [DOI: 10.1016/j.cld.2014.09.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
90 Li BA, Liu J, Hou J, Tang J, Zhang J, Xu J, Song YJ, Liu AX, Zhao J, Guo JX, Chen L, Wang H, Yang LH, Lu J, Mao YL. Autoantibodies in Chinese patients with chronic hepatitis B: Prevalence and clinical associations. World J Gastroenterol 2015; 21(1): 283-291 [PMID: 25574103 DOI: 10.3748/wjg.v21.i1.283] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
91 Villalta D, Sorrentino MC, Girolami E, Tampoia M, Alessio MG, Brusca I, Daves M, Porcelli B, Barberio G, Bizzaro N. Autoantibody profiling of patients with primary biliary cirrhosis using a multiplexed line-blot assay. Clinica Chimica Acta 2015;438:135-8. [DOI: 10.1016/j.cca.2014.08.024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
92 Nakamura M, Kondo H, Tanaka A, Komori A, Ito M, Yamamoto K, Ohira H, Zeniya M, Hashimoto E, Honda M. Autoantibody status and histological variables influence biochemical response to treatment and long-term outcomes in Japanese patients with primary biliary cirrhosis. Hepatol Res. 2015;45:846-855. [PMID: 25220608 DOI: 10.1111/hepr.12423] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
93 Ali AH, Carey EJ, Lindor KD. Diagnosis and management of primary biliary cirrhosis. Expert Review of Clinical Immunology 2014;10:1667-78. [DOI: 10.1586/1744666x.2014.979792] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
94 Dyson JK, Webb G, Hirschfield GM, Lohse A, Beuers U, Lindor K, Jones DE. Unmet clinical need in autoimmune liver diseases. J Hepatol. 2015;62:208-218. [PMID: 25234946 DOI: 10.1016/j.jhep.2014.09.010] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
95 Himoto T, Tanaka N, Saito A, Muro Y, Sugiura K, Tani J, Miyoshi H, Morishita A, Yoneyama H, Haba R. Diversity of humoral responses to the centromere proteins among HCV-related chronic liver disease, PBC and AIH patients. Clin Res Hepatol Gastroenterol. 2015;39:222-229. [PMID: 25220385 DOI: 10.1016/j.clinre.2014.08.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
96 Hu SL, Zhao FR, Hu Q, Chen WX. Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis. PLoS One 2014;9:e101916. [PMID: 25010534 DOI: 10.1371/journal.pone.0101916] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
97 Lammers WJ, Kowdley KV, Buuren HRV. Predicting outcome in primary biliary cirrhosis. Annals of Hepatology 2014;13:316-26. [DOI: 10.1016/s1665-2681(19)30838-5] [Cited by in Crossref: 31] [Article Influence: 3.9] [Reference Citation Analysis]
98 Chantran Y, Ballot E, Johanet C. Autoantibodies in primary biliary cirrhosis: Antinuclear envelope autoantibodies. Clinics and Research in Hepatology and Gastroenterology 2014;38:256-8. [DOI: 10.1016/j.clinre.2013.10.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
99 Tsuboi H, Ohira H, Asashima H, Tsuzuki S, Iizuka M, Matsuo N, Kondo Y, Matsumoto I, Sumida T. Anti-M3 muscarinic acetylcholine receptor antibodies in patients with primary biliary cirrhosis. Hepatol Res 2014;44:E471-9. [PMID: 24750585 DOI: 10.1111/hepr.12346] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
100 Yamagiwa S, Kamimura H, Takamura M, Aoyagi Y. Autoantibodies in primary biliary cirrhosis: Recent progress in research on the pathogenetic and clinical significance. World J Gastroenterol 2014; 20(10): 2606-2612 [PMID: 24627596 DOI: 10.3748/wjg.v20.i10.2606] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
101 Ohira H, Watanabe H. Pathophysiology and recent findings of primary biliary cirrhosis complicated by systemic sclerosis: PBC complicated by systemic sclerosis. Hepatol Res 2014;44:377-83. [DOI: 10.1111/hepr.12285] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
102 Joshita S, Umemura T, Nakamura M, Katsuyama Y, Shibata S, Kimura T, Morita S, Komatsu M, Matsumoto A, Yoshizawa K. STAT4 gene polymorphisms are associated with susceptibility and ANA status in primary biliary cirrhosis. Dis Markers. 2014;2014:727393. [PMID: 24648611 DOI: 10.1155/2014/727393] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
103 Bogdanos DP, Smyk DS, Invernizzi P, Rigopoulou EI, Blank M, Sakkas L, Pouria S, Shoenfeld Y. Tracing environmental markers of autoimmunity: introducing the infectome. Immunol Res 2013;56:220-40. [PMID: 23592050 DOI: 10.1007/s12026-013-8399-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
104 Bowlus CL, Gershwin ME. The diagnosis of primary biliary cirrhosis. Autoimmun Rev. 2014;13:441-444. [PMID: 24424173 DOI: 10.1016/j.autrev.2014.01.041] [Cited by in Crossref: 82] [Cited by in F6Publishing: 75] [Article Influence: 10.3] [Reference Citation Analysis]
105 Shi TY, Zhang FC. Role of autoimmunity in primary biliary cirrhosis. World J Gastroenterol. 2012;18:7141-7148. [PMID: 23326118 DOI: 10.3748/wjgv.18.i48.7141] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Working Subgroup (English version) for Clinical Practice Guidelines for Primary Biliary Cirrhosis. Guidelines for the management of primary biliary cirrhosis: The Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. Hepatol Res 2014;44 Suppl S1:71-90. [PMID: 24397841 DOI: 10.1111/hepr.12270] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 7.0] [Reference Citation Analysis]
107 Takada K, Suzuki K, Matsumoto M, Okada M, Nakanishi T, Horikoshi H, Higuchi T, Ohsuzu F. Primary biliary cirrhosis in female subjects with sicca-associated antibodies. Modern Rheumatology 2014;17:486-91. [DOI: 10.3109/s10165-007-0631-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
108 Tanaka T, Yamashiki N, Sugawara Y, Tamura S, Nakamura M, Kaneko J, Aoki T, Sakamoto Y, Hasegawa K, Kokudo N. Chronologic changes of explanted liver volume and the use of ursodeoxycholic acid in patients with end-stage primary biliary cirrhosis. Hepatol Res 2014;44:993-9. [PMID: 24298893 DOI: 10.1111/hepr.12283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
109 Czul F, Peyton A, Levy C. Primary biliary cirrhosis: therapeutic advances. Clin Liver Dis. 2013;17:229-242. [PMID: 23540499 DOI: 10.1016/j.cld.2012.12.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
110 Monoe K, Takahashi A, Abe K, Kanno Y, Watanabe H, Ohira H. Evaluation of nail fold capillaroscopy findings in patients with primary biliary cirrhosis: Nail fold capillaroscopy in PBC patients. Hepatol Res 2014;44:E129-36. [DOI: 10.1111/hepr.12255] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
111 Aiba Y, Harada K, Komori A, Ito M, Shimoda S, Nakamura H, Nagaoka S, Abiru S, Migita K, Ishibashi H, Nakanuma Y, Nishida N, Kawashima M, Tokunaga K, Yatsuhashi H, Nakamura M. Systemic and local expression levels of TNF-like ligand 1A and its decoy receptor 3 are increased in primary biliary cirrhosis. Liver Int 2014;34:679-88. [PMID: 24016146 DOI: 10.1111/liv.12296] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
112 Tang J, Lu J, Yan HP. Diagnostic and predictive significance of autoantibody profiles in autoimmune liver disease. Shijie Huaren Xiaohua Zazhi 2013; 21(25): 2544-2550 [DOI: 10.11569/wcjd.v21.i25.2544] [Reference Citation Analysis]
113 Volta U, Caio G, Tovoli F, De Giorgio R. Gut-liver axis: an immune link between celiac disease and primary biliary cirrhosis. Expert Rev Gastroenterol Hepatol 2013;7:253-61. [PMID: 23445234 DOI: 10.1586/egh.13.5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
114 Yoshioka Y, Taniai M, Hashimoto E, Haruta I, Shiratori K. Clinical profile of primary biliary cirrhosis with features of autoimmune hepatitis: Importance of corticosteroid therapy. Hepatol Res 2014;44:947-55. [PMID: 23879195 DOI: 10.1111/hepr.12210] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
115 Liberal R, Grant CR, Sakkas L, Bizzaro N, Bogdanos DP. Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis. Clin Res Hepatol Gastroenterol. 2013;37:572-585. [PMID: 23876351 DOI: 10.1016/j.clinre.2013.04.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
116 Zhao DT, Liao HY, Zhang X, Liu YM, Zhao Y, Zhang HP, Sun LM, Ma YX, Yan HP. Human leucocyte antigen alleles and haplotypes and their associations with antinuclear antibodies features in Chinese patients with primary biliary cirrhosis. Liver Int 2014;34:220-6. [PMID: 23809616 DOI: 10.1111/liv.12236] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
117 Gatselis NK, Zachou K, Norman GL, Gabeta S, Papamichalis P, Koukoulis GK, Dalekos GN. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. Autoimmunity. 2013;46:471-479. [PMID: 23777462 DOI: 10.3109/08916934.2013.801461] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
118 Harada K, Kakuda Y, Nakamura M, Shimoda S, Nakanuma Y. Clinicopathological significance of serum fractalkine in primary biliary cirrhosis. Dig Dis Sci. 2013;58:3037-3043. [PMID: 23765258 DOI: 10.1007/s10620-013-2734-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
119 Achenza MI, Meda F, Brunetta E, Selmi C. Serum autoantibodies for the diagnosis and management of autoimmune liver diseases. Expert Rev Gastroenterol Hepatol. 2012;6:717-729. [PMID: 23237257 DOI: 10.1586/egh.12.58] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
120 Raszeja-Wyszomirska J, Wunsch E, Kempinska-Podhorodecka A, Smyk DS, Bogdanos DP, Milkiewicz M, Milkiewicz P. TRAF1-C5 affects quality of life in patients with primary biliary cirrhosis. Clin Dev Immunol. 2013;2013:510547. [PMID: 23710202 DOI: 10.1155/2013/510547] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
121 Ohishi Y, Nakamuta M, Ishikawa N, Saitoh O, Nakamura H, Aiba Y, Komori A, Migita K, Yatsuhashi H, Fukushima N, Kohjima M, Yoshimoto T, Fukuizumi K, Ishibashi M, Nishino T, Shirabe K, Taketomi A, Maehara Y, Ishibashi H, Nakamura M; PBC Study Group of NHOSLJ. Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients. J Gastroenterol 2014;49:332-42. [DOI: 10.1007/s00535-013-0795-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
122 Rigopoulou EI, Dalekos GN. Molecular diagnostics of primary biliary cirrhosis. Expert Opin Med Diagn. 2008;2:621-634. [PMID: 23495774 DOI: 10.1517/17530059.2.6.621] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
123 Himoto T, Nishioka M. Autoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis. Auto Immun Highlights. 2013;4:39-53. [PMID: 26000142 DOI: 10.1007/s13317-013-0046-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
124 Shi TY, Zhang LN, Chen H, Wang L, Shen M, Zhang X, Zhang FC. Risk factors for hepatic decompensation in patients with primary biliary cirrhosis. World J Gastroenterol 2013; 19(7): 1111-1118 [PMID: 23467321 DOI: 10.3748/wjg.v19.i7.1111] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
125 Song G, Hu C, Zhu H, Wang L, Zhang F, Li Y, Wu L. New centromere autoantigens identified in systemic sclerosis using centromere protein microarrays. J Rheumatol. 2013;40:461-468. [PMID: 23418382 DOI: 10.3899/jrheum.120264] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
126 Shi TY, Zhang FC. Role of autoimmunity in primary biliary cirrhosis. World J Gastroenterol 2012; 18(48): 7141-7148 [PMID: 23326118 DOI: 10.3748/wjg.v18.i48.7141] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
127 Mandai S, Kanda E, Arai Y, Hirasawa S, Hirai T, Aki S, Inaba N, Aoyagi M, Tanaka H, Ikeda T. Anti-centromere antibody is an independent risk factor for chronic kidney disease in patients with primary biliary cirrhosis. Clin Exp Nephrol. 2013;17:405-410. [PMID: 23268283 DOI: 10.1007/s10157-012-0724-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
128 Bogdanos DP, Smyk DS, Invernizzi P, Rigopoulou EI, Blank M, Pouria S, Shoenfeld Y. Infectome: a platform to trace infectious triggers of autoimmunity. Autoimmun Rev. 2013;12:726-740. [PMID: 23266520 DOI: 10.1016/j.autrev.2012.12.005] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 6.5] [Reference Citation Analysis]
129 Dellavance A, Cançado EL, Abrantes-Lemos CP, Harriz M, Marvulle V, Andrade LE. Humoral autoimmune response heterogeneity in the spectrum of primary biliary cirrhosis. Hepatol Int 2013;7:775-84. [PMID: 23853697 DOI: 10.1007/s12072-012-9413-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
130 Al-Harthy N, Kumagi T. Natural history and management of primary biliary cirrhosis. Hepat Med. 2012;4:61-71. [PMID: 24367233 DOI: 10.2147/HMER.S25998] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.2] [Reference Citation Analysis]
131 Koutsoumpas AL, Kriese S, Rigopoulou EI. Popular and unpopular infectious agents linked to primary biliary cirrhosis. Auto Immun Highlights 2012;3:95-104. [PMID: 26000132 DOI: 10.1007/s13317-012-0039-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
132 Milkiewicz M, Caballería L, Smyk DS, Milkiewicz P. Predicting and preventing autoimmunity: the case of anti-mitochondrial antibodies. Auto Immun Highlights 2012;3:105-12. [PMID: 26000133 DOI: 10.1007/s13317-012-0038-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
133 Hu C, Deng C, Zhang S, Song G, Li L, Li X, Wang L, Zhang F, Li Y. Clinical significance and prevalence of anti-Saccharomyces cerevisiae antibody in Chinese patients with primary biliary cirrhosis. Clin Exp Med 2013;13:245-50. [DOI: 10.1007/s10238-012-0207-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
134 Zografos TA, Gatselis N, Zachou K, Liaskos C, Gabeta S, Koukoulis GK, Dalekos GN. Primary biliary cirrhosis-specific autoantibodies in first degree relatives of Greek primary biliary cirrhosis patients. World J Gastroenterol 2012; 18(34): 4721-4728 [PMID: 23002341 DOI: 10.3748/wjg.v18.i34.4721] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
135 Yang CY, Leung PS, Yang GX, Kenny TP, Zhang W, Coppel R, Norman GL, Ansari AA, Mackay IR, Worman HJ. Epitope-specific anti-nuclear antibodies are expressed in a mouse model of primary biliary cirrhosis and are cytokine-dependent. Clin Exp Immunol. 2012;168:261-267. [PMID: 22519587 DOI: 10.1111/j.1365-2249.2012.04577.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
136 Hu CJ, Song G, Huang W, Liu GZ, Deng CW, Zeng HP, Wang L, Zhang FC, Zhang X, Jeong JS. Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays. Mol Cell Proteomics. 2012;11:669-680. [PMID: 22647870 DOI: 10.1074/mcp.m111.015529] [Cited by in Crossref: 62] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
137 Smyk DS, Rigopoulou EI, Pares A, Billinis C, Burroughs AK, Muratori L, Invernizzi P, Bogdanos DP. Sex differences associated with primary biliary cirrhosis. Clin Dev Immunol. 2012;2012:610504. [PMID: 22693524 DOI: 10.1155/2012/610504] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
138 Rigopoulou EI, Smyk DS, Matthews CE, Billinis C, Burroughs AK, Lenzi M, Bogdanos DP. Epstein-barr virus as a trigger of autoimmune liver diseases. Adv Virol 2012;2012:987471. [PMID: 22693505 DOI: 10.1155/2012/987471] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
139 Uibo R, Kisand K, Yang CY, Gershwin ME. Primary biliary cirrhosis: a multi-faced interactive disease involving genetics, environment and the immune response. APMIS. 2012;120:857-871. [PMID: 23009110 DOI: 10.1111/j.1600-0463.2012.02914.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
140 Hirschfield GM. Diagnosis of primary biliary cirrhosis. Best Pract Res Clin Gastroenterol. 2011;25:701-712. [PMID: 22117636 DOI: 10.1016/j.bpg.2011.10.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
141 Granito A, Muratori P, Quarneti C, Pappas G, Cicola R, Muratori L. Antinuclear antibodies as ancillary markers in primary biliary cirrhosis. Expert Rev Mol Diagn 2012;12:65-74. [PMID: 22133120 DOI: 10.1586/erm.11.82] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
142 Duarte-Rey C, Bogdanos D, Yang CY, Roberts K, Leung PS, Anaya JM, Worman HJ, Gershwin ME. Primary biliary cirrhosis and the nuclear pore complex. Autoimmun Rev. 2012;11:898-902. [PMID: 22487189 DOI: 10.1016/j.autrev.2012.03.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
143 Trivedi PJ, Cullen S. Etiopathogenesis of primary biliary cirrhosis: an overview of recent developments. Hepatol Int 2013;7:28-47. [PMID: 26201620 DOI: 10.1007/s12072-012-9362-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
144 Imura-Kumada S, Hasegawa M, Matsushita T, Hamaguchi Y, Encabo S, Shums Z, Norman GL, Takehara K, Fujimoto M. High prevalence of primary biliary cirrhosis and disease-associated autoantibodies in Japanese patients with systemic sclerosis. Mod Rheumatol. 2012;22:892-898. [PMID: 22327744 DOI: 10.3109/s10165-012-0607-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
145 Umemura T, Joshita S, Ichijo T, Yoshizawa K, Katsuyama Y, Tanaka E, Ota M; Shinshu PBC Study Group. Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis. Hepatology 2012;55:506-11. [PMID: 21953406 DOI: 10.1002/hep.24705] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 5.4] [Reference Citation Analysis]
146 Smyk D, Rigopoulou EI, Bizzaro N, Bogdanos DP. Hair dyes as a risk for autoimmunity: from systemic lupus erythematosus to primary biliary cirrhosis. Auto Immun Highlights. 2013;4:1-9. [PMID: 26000137 DOI: 10.1007/s13317-011-0027-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
147 Selmi C, Meroni PL, Gershwin ME. Primary biliary cirrhosis and Sjögren’s syndrome: autoimmune epithelitis. J Autoimmun. 2012;39:34-42. [PMID: 22178199 DOI: 10.1016/j.jaut.2011.11.005] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 7.2] [Reference Citation Analysis]
148 Minz RW, Kaur N, Anand S, Aggarwal R, Saikia B, Das A, Chawla YK. Complete spectrum of AMA-M2 positive liver disease in north India. Hepatol Int 2012;6:790-5. [PMID: 26201527 DOI: 10.1007/s12072-011-9326-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
149 Hirschfield GM. Autoimmune hepatitis - learning about your patients from their autoantibody profiles. Liver Int 2012;32:5-7. [DOI: 10.1111/j.1478-3231.2011.02658.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
150 Rigamonti C, Bogdanos DP, Mytilinaiou MG, Smyk DS, Rigopoulou EI, Burroughs AK. Primary biliary cirrhosis associated with systemic sclerosis: diagnostic and clinical challenges. Int J Rheumatol 2011;2011:976427. [PMID: 22187566 DOI: 10.1155/2011/976427] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
151 Ohira H, Abe K, Takahashi A. Involvement of the liver in rheumatic diseases. Clin J Gastroenterol 2012;5:9-14. [DOI: 10.1007/s12328-011-0271-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Ali AH, Sinakos E, Silveira MG, Jorgensen RA, Angulo P, Lindor KD. Varices in early histological stage primary biliary cirrhosis. J Clin Gastroenterol. 2011;45:e66-e71. [PMID: 20856137 DOI: 10.1097/mcg.0b013e3181f18c4e] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
153 Fukushima K, Ueno Y, Shimosegawa T. Treatment of Primary Biliary Cirrhosis: A new challenge? Hepatol Res 2010;40:61-8. [PMID: 20156299 DOI: 10.1111/j.1872-034X.2009.00605.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
154 Smyk DS, Mytilinaiou MG, Milkiewicz P, Rigopoulou EI, Invernizzi P, Bogdanos DP. Towards systemic sclerosis and away from primary biliary cirrhosis: the case of PTPN22. Auto Immun Highlights 2012;3:1-9. [PMID: 26000122 DOI: 10.1007/s13317-011-0023-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
155 Nakamura M, Komori A, Ito M, Kondo H, Aiba Y, Migita K, Nagaoka S, Ohata K, Yano K, Abiru S. Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis. Hepatol Res. 2007;37 Suppl 3:S412-S419. [PMID: 17931196 DOI: 10.1111/j.1872-034x.2007.00244.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
156 Yanagisawa N, Haruta I, Kikuchi K, Shibata N, Yagi J. Are dysregulated inflammatory responses to commensal bacteria involved in the pathogenesis of hepatobiliary-pancreatic autoimmune disease? An analysis using mice models of primary biliary cirrhosis and autoimmune pancreatitis. ISRN Gastroenterol 2011;2011:513514. [PMID: 21991516 DOI: 10.5402/2011/513514] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
157 Hu C, Deng C, Song G, Zhang W, Zhang S, Li X, Li P, Zhang F, Li Y. Prevalence of autoimmune liver disease related autoantibodies in Chinese patients with primary biliary cirrhosis. Dig Dis Sci. 2011;56:3357-3363. [PMID: 21660486 DOI: 10.1007/s10620-011-1756-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
158 Kobayashi M, Furuta K, Kitamura H, Oguchi K, Arai M, Koike S, Nakazawa K. A case of primary biliary cirrhosis that complicated with combined hepatocellular and cholangiocellular carcinoma. Clin J Gastroenterol 2011;4:236-41. [PMID: 26189527 DOI: 10.1007/s12328-011-0223-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
159 Aiba Y, Nakamura M, Joshita S, Inamine T, Komori A, Yoshizawa K, Umemura T, Horie H, Migita K, Yatsuhashi H. Genetic polymorphisms in CTLA4 and SLC4A2 are differentially associated with the pathogenesis of primary biliary cirrhosis in Japanese patients. J Gastroenterol. 2011;46:1203-1212. [PMID: 21594562 DOI: 10.1007/s00535-011-0417-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
160 Smyk D, Cholongitas E, Kriese S, Rigopoulou EI, Bogdanos DP. Primary biliary cirrhosis: family stories. Autoimmune Dis. 2011;2011:189585. [PMID: 21687641 DOI: 10.4061/2011/189585] [Cited by in Crossref: 13] [Cited by in F6Publishing: 25] [Article Influence: 1.2] [Reference Citation Analysis]
161 Nakanuma Y, Harada K. The role of the pathologist in diagnosing and grading biliary diseases. Clinics and Research in Hepatology and Gastroenterology 2011;35:347-52. [DOI: 10.1016/j.clinre.2011.01.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
162 Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet. 2011;377:1600-1609. [PMID: 21529926 DOI: 10.1016/s0140-6736(10)61965-4] [Cited by in Crossref: 193] [Cited by in F6Publishing: 85] [Article Influence: 17.5] [Reference Citation Analysis]
163 Azemoto N, Kumagi T, Abe M, Konishi I, Matsuura B, Hiasa Y, Onji M. Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis: Biochemical response to UDCA in PBC. Hepatology Research 2011;41:310-7. [DOI: 10.1111/j.1872-034x.2011.00782.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
164 Berg PA. The role of the innate immune recognition system in the pathogenesis of primary biliary cirrhosis: a conceptual view. Liver Int. 2011;31:920-931. [PMID: 21733082 DOI: 10.1111/j.1478-3231.2011.02457.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
165 Ning QY, Wu JZ, Li GJ, Zang N, Hu DF, Wu JL, Chen MW, Wan PQ. Screening of differentially expressed low-abundance proteins among serum samples from patients with different HBV-related hepatic diseases by SELDI-TOF-MS. Shijie Huaren Xiaohua Zazhi 2011; 19(2): 143-150 [DOI: 10.11569/wcjd.v19.i2.143] [Reference Citation Analysis]
166 Medina JF. Role of the Anion Exchanger 2 in the Pathogenesis and Treatment of Primary Biliary Cirrhosis. Dig Dis 2011;29:103-12. [DOI: 10.1159/000324144] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
167 Bizzaro N, Covini G, Rosina F, Muratori P, Tonutti E, Villalta D, Pesente F, Alessio MG, Tampoia M, Antico A, Platzgummer S, Porcelli B, Terzuoli L, Liguori M, Bassetti D, Brusca I, Almasio PL, Tarantino G, Bonaguri C, Agostinis P, Bredi E, Tozzoli R, Invernizzi P, Selmi C. Overcoming a “Probable” Diagnosis in Antimitochondrial Antibody Negative Primary Biliary Cirrhosis: Study of 100 Sera and Review of the Literature. Clinic Rev Allerg Immunol 2012;42:288-97. [DOI: 10.1007/s12016-010-8234-y] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
168 Bogdanos DP, Komorowski L. Disease-specific autoantibodies in primary biliary cirrhosis. Clin Chim Acta. 2011;412:502-512. [PMID: 21185272 DOI: 10.1016/j.cca.2010.12.019] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 5.6] [Reference Citation Analysis]
169 Inamine T, Nakamura M, Kawauchi A, Shirakawa Y, Hashiguchi H, Aiba Y, Taketomi A, Shirabe K, Nakamuta M, Hayashi S. A polymorphism in the integrin αV subunit gene affects the progression of primary biliary cirrhosis in Japanese patients. J Gastroenterol. 2011;46:676-686. [PMID: 21116829 DOI: 10.1007/s00535-010-0351-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
170 Sasaki M, Nakanuma Y. Biliary epithelial apoptosis, autophagy, and senescence in primary biliary cirrhosis. Hepat Res Treat. 2010;2010:205128. [PMID: 21152179 DOI: 10.1155/2010/205128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
171 Selmi C, Mackay IR, Gershwin ME. The autoimmunity of primary biliary cirrhosis and the clonal selection theory. Immunol Cell Biol 2011;89:70-80. [PMID: 20975735 DOI: 10.1038/icb.2010.126] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
172 Sfakianaki O, Koulentaki M, Tzardi M, Tsangaridou E, Theodoropoulos PA, Castanas E, Kouroumalis EA. Peri-nuclear antibodies correlate with survival in Greek primary biliary cirrhosis patients. World J Gastroenterol 2010; 16(39): 4938-4943 [PMID: 20954280 DOI: 10.3748/wjg.v16.i39.4938] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
173 Liu H, Norman GL, Shums Z, Worman HJ, Krawitt EL, Bizzaro N, Vergani D, Bogdanos DP, Dalekos GN, Milkiewicz P. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun. 2010;35:436-442. [PMID: 20932720 DOI: 10.1016/j.jaut.2010.09.005] [Cited by in Crossref: 93] [Cited by in F6Publishing: 85] [Article Influence: 7.8] [Reference Citation Analysis]
174 Geri G, Cacoub P. [Hepatic granulomas]. Rev Med Interne 2011;32:560-6. [PMID: 20832918 DOI: 10.1016/j.revmed.2010.06.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
175 Hu CJ, Zhang FC, Li YZ, Zhang X. Primary biliary cirrhosis: What do autoantibodies tell us? World J Gastroenterol 2010; 16(29): 3616-3629 [PMID: 20677333 DOI: 10.3748/wjg.v16.i29.3616] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
176 Gatselis NK, Zachou K, Dalekos GN. Early primary biliary cirrhosis: a new association with erythema nodosum of unknown origin. Gastroenterol Res Pract 2010;2010:121620. [PMID: 20706542 DOI: 10.1155/2010/121620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
177 Himoto T, Murota M, Yoneyama H, Deguchi A, Kurokochi K, Senda S, Haba R, Watanabe S, Nishioka M, Masaki T. Clinical characteristics of patients with autoimmune hepatitis seropositive for anticentromere antibody: ACA-positive autoimmune hepatitis. Hepatology Research 2010;40:786-92. [DOI: 10.1111/j.1872-034x.2010.00684.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
178 Zeman MV, Hirschfield GM. Autoantibodies and liver disease: uses and abuses. Can J Gastroenterol 2010;24:225-31. [PMID: 20431809 DOI: 10.1155/2010/431913] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
179 Silveira MG, Brunt EM, Heathcote J, Gores GJ, Lindor KD, Mayo MJ. American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology 2010;52:349-59. [PMID: 20578151 DOI: 10.1002/hep.23637] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 5.2] [Reference Citation Analysis]
180 Joshita S, Umemura T, Yoshizawa K, Katsuyama Y, Tanaka E, Nakamura M, Ishibashi H, Ota M; Shinshu PBC Study Group. Association analysis of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with primary biliary cirrhosis in Japanese patients. J Hepatol 2010;53:537-41. [PMID: 20557968 DOI: 10.1016/j.jhep.2010.03.017] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
181 Czaja AJ. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci. 2010;55:2144-2161. [PMID: 20464491 DOI: 10.1007/s10620-010-1268-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
182 Invernizzi P, Selmi C, Gershwin ME. Update on primary biliary cirrhosis. Dig Liver Dis. 2010;42:401-408. [PMID: 20359968 DOI: 10.1016/j.dld.2010.02.014] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
183 Nakamura M, Yasunami M, Kondo H, Horie H, Aiba Y, Komori A, Migita K, Yatsuhashi H, Ito M, Shimoda S, Ishibashi H; PBC Study Group in NHOSLJ. Analysis of HLA-DRB1 polymorphisms in Japanese patients with primary biliary cirrhosis (PBC): The HLA-DRB1polymorphism determines the relative risk of antinuclear antibodies for disease progression in PBC: HLA-DRB1 polymorphism in Japanese patients with PBC. Hepatology Research 2010;40:494-504. [DOI: 10.1111/j.1872-034x.2010.00631.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
184 Tsangaridou E, Polioudaki H, Sfakianaki R, Samiotaki M, Tzardi M, Koulentaki M, Panayotou G, Kouroumalis E, Castanas E, Theodoropoulos PA. Differential detection of nuclear envelope autoantibodies in primary biliary cirrhosis using routine and alternative methods. BMC Gastroenterol. 2010;10:28. [PMID: 20205958 DOI: 10.1186/1471-230x-10-28] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
185 Liaskos C, Norman GL, Moulas A, Garagounis A, Goulis I, Rigopoulou EI, Dalekos GN. Prevalence of gastric parietal cell antibodies and intrinsic factor antibodies in primary biliary cirrhosis. Clinica Chimica Acta 2010;411:411-5. [DOI: 10.1016/j.cca.2009.12.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
186 Chahine MN, Pierce GN. Therapeutic Targeting of Nuclear Protein Import in Pathological Cell Conditions. Pharmacol Rev 2009;61:358-72. [DOI: 10.1124/pr.108.000620] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
187 Lu BR, Mack CL. Inflammation and biliary tract injury. Curr Opin Gastroenterol 2009;25:260-4. [PMID: 19396964 DOI: 10.1097/mog.0b013e328325aa10] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
188 Assassi S, Fritzler MJ, Arnett FC, Norman GL, Shah KR, Gourh P, Manek N, Perry M, Ganesh D, Rahbar MH, Mayes MD. Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol 2009;36:2250-6. [PMID: 19723904 DOI: 10.3899/jrheum.090340] [Cited by in Crossref: 69] [Cited by in F6Publishing: 53] [Article Influence: 5.3] [Reference Citation Analysis]
189 Selmi C, Gershwin ME. The role of environmental factors in primary biliary cirrhosis. Trends Immunol 2009;30:415-20. [PMID: 19643668 DOI: 10.1016/j.it.2009.05.006] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 4.3] [Reference Citation Analysis]
190 Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology 2009;50:291-308. [PMID: 19554543 DOI: 10.1002/hep.22906] [Cited by in Crossref: 886] [Cited by in F6Publishing: 756] [Article Influence: 68.2] [Reference Citation Analysis]
191 Takada K, Suzuki K, Matsumoto M, Okada M, Nakanishi T, Horikoshi H, Higuchi T, Ohsuzu F. Clinical characteristics of patients with both anti-U1RNP and anti-centromere antibodies. Scand J Rheumatol. 2008;37:360-364. [PMID: 18686191 DOI: 10.1080/03009740802116190] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
192 Ohishi Y, Nakamura M, Iio N, Higa S, Inayoshi M, Aiba Y, Komori A, Omagari K, Ishibashi H, Tsukamoto K. Single-nucleotide polymorphism analysis of the multidrug resistance protein 3 gene for the detection of clinical progression in Japanese patients with primary biliary cirrhosis. Hepatology 2008;48:853-62. [PMID: 18671305 DOI: 10.1002/hep.22382] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
193 Hirschfield GM, Heathcote EJ. Antimitochondrial antibody-negative primary biliary cirrhosis. Clin Liver Dis. 2008;12:323-331; viii-ix. [PMID: 18456183 DOI: 10.1016/j.cld.2008.02.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
194 Kumagi T, Onji M. Presentation and diagnosis of primary biliary cirrhosis in the 21st century. Clin Liver Dis 2008;12:243-59; vii. [PMID: 18456178 DOI: 10.1016/j.cld.2008.02.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
195 Muratori L, Granito A, Muratori P, Pappas G, Bianchi FB. Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value. Clin Liver Dis. 2008;12:261-276; vii. [PMID: 18456179 DOI: 10.1016/j.cld.2008.02.009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
196 Shimoda S, Miyakawa H, Nakamura M, Ishibashi H, Kikuchi K, Kita H, Niiro H, Arinobu Y, Ono N, Mackay IR, Gershwin ME, Akashi K. CD4 T-cell autoreactivity to the mitochondrial autoantigen PDC-E2 in AMA-negative primary biliary cirrhosis. J Autoimmun 2008;31:110-5. [PMID: 18644699 DOI: 10.1016/j.jaut.2008.05.003] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 4.1] [Reference Citation Analysis]
197 Himoto T, Nakai S, Kinekawa F, Yoneyama H, Deguchi A, Kurokochi K, Masaki T, Senda S, Haba R, Watanabe S. Clinical characteristics of patients with hepatitis C virus-related chronic liver disease seropositive for anticentromere antibody. Dig Dis Sci. 2009;54:360-368. [PMID: 18629643 DOI: 10.1007/s10620-008-0359-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
198 Wesierska-Gadek J, Klima A, Ranftler C, Komina O, Hanover J, Invernizzi P, Penner E. Characterization of the antibodies to p62 nucleoporin in primary biliary cirrhosis using human recombinant antigen. J Cell Biochem. 2008;104:27-37. [PMID: 17960595 DOI: 10.1002/jcb.21595] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
199 Sasaki M, Ikeda H, Yamaguchi J, Nakada S, Nakanuma Y. Telomere shortening in the damaged small bile ducts in primary biliary cirrhosis reflects ongoing cellular senescence. Hepatology 2008;48:186-95. [PMID: 18536059 DOI: 10.1002/hep.22348] [Cited by in Crossref: 88] [Cited by in F6Publishing: 75] [Article Influence: 6.3] [Reference Citation Analysis]
200 Lleo A, Invernizzi P, Mackay IR, Prince H, Zhong RQ, Gershwin ME. Etiopathogenesis of primary biliary cirrhosis. World J Gastroenterol 2008; 14(21): 3328-3337 [PMID: 18528930 DOI: 10.3748/wjg.14.3328] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 61] [Article Influence: 4.9] [Reference Citation Analysis]
201 Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: Current diagnostic and clinical challenges. World J Gastroenterol 2008; 14(21): 3374-3387 [PMID: 18528935 DOI: 10.3748/wjg.14.3374] [Cited by in CrossRef: 145] [Cited by in F6Publishing: 122] [Article Influence: 10.4] [Reference Citation Analysis]
202 Kumagi T, Alswat K, Hirschfield GM, Heathcote J. New insights into autoimmune liver diseases. Hepatol Res. 2008;38:745-761. [PMID: 18462376 DOI: 10.1111/j.1872-034x.2008.00366.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
203 Abe M, Onji M. Natural history of primary biliary cirrhosis. Hepatol Res 2008;38:639-45. [PMID: 18462379 DOI: 10.1111/j.1872-034X.2008.00351.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
204 Hirschfield GM, Heathcote EJ. Primary biliary cirrhosis: the future. Clin Liver Dis 2008;12:473-9; xi. [PMID: 18456192 DOI: 10.1016/j.cld.2008.02.002] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
205 Gao L, Tian X, Liu B, Zhang F. The value of antinuclear antibodies in primary biliary cirrhosis. Clin Exp Med. 2008;8:9-15. [PMID: 18385935 DOI: 10.1007/s10238-008-0150-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
206 Gershwin ME, Mackay IR. The causes of primary biliary cirrhosis: Convenient and inconvenient truths. Hepatology 2008;47:737-45. [PMID: 18098322 DOI: 10.1002/hep.22042] [Cited by in Crossref: 210] [Cited by in F6Publishing: 197] [Article Influence: 15.0] [Reference Citation Analysis]
207 Rigopoulou EI, Davies ET, Bogdanos DP, Liaskos C, Mytilinaiou M, Koukoulis GK, Dalekos GN, Vergani D. Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. Liver Int. 2007;27:1226-1231. [PMID: 17919234 DOI: 10.1111/j.1478-3231.2007.01586.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 3.2] [Reference Citation Analysis]
208 Kumagi T, Heathcote EJ. Primary biliary cirrhosis. Orphanet J Rare Dis 2008;3:1. [PMID: 18215315 DOI: 10.1186/1750-1172-3-1] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 4.8] [Reference Citation Analysis]
209 Santiago M, Baron M, Miyachi K, Fritzler MJ, Abu-Hakima M, Leclercq S, Bell M, Hudson M, Mathieu JP, Taillefer S. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol. 2008;27:77-83. [PMID: 17570008 DOI: 10.1007/s10067-007-0656-4] [Cited by in Crossref: 69] [Cited by in F6Publishing: 55] [Article Influence: 4.6] [Reference Citation Analysis]
210 Bogdanos DP, Liaskos C, Pares A, Norman G, Rigopoulou EI, Caballeria L, Dalekos GN, Rodes J, Vergani D. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. Hepatology 2007;45:1583; author reply 1583-4. [PMID: 17538935 DOI: 10.1002/hep.21678] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 3.1] [Reference Citation Analysis]
211 Ueno Y, Moritoki Y, Shimosegawa T, Gershwin ME. Primary biliary cirrhosis: what we know and what we want to know about human PBC and spontaneous PBC mouse models. J Gastroenterol 2007;42:189-95. [PMID: 17380276 DOI: 10.1007/s00535-007-2019-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
212 Nakamura M. Reply:. Hepatology 2007;45:1583-4. [DOI: 10.1002/hep.21706] [Reference Citation Analysis]